Athira Pharma, Inc. — Director's Dealing 2023

Mar 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2023-03-24

Reporting Person: CHURCH KEVIN (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-24	Common Stock	M	6410	$1.35	Acquired	68462	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-24	Stock Option (Right to Buy)	$1.35	M	6410	Disposed	2028-12-17	Common Stock (6410)	Direct

Footnotes

F1: One-fourth of the shares subject to the option vested on January 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.